Neurocrine Seizure Drug Failure Draws Concern For Additional Program
Executive Summary
The company said two Phase II programs – NBI-921352 in focal onset seizure and NBI-1065846 in anhedonia – failed. It is investigating potential read-through to another seizure disorder for ‘352.